Exploring the effect of Silymarin on generalized hypoxia-induced liver damage

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N112

Enrollment

Registered

2019-05-28

Start date

2019-01-05

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxia. Acute respiratory failure with hypoxia

Interventions

Intervention 1: Intervention group: We treat patients with 280 milligram Silymarin orally(mouth or gavage) every 8 hours for 3 days. Intervention 2: Control group: We treat patients with placebo every

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Hypoxia patients Age older than 18 years

Exclusion criteria

Exclusion criteria: Death of the patient Dissatisfaction

Design outcomes

Primary

Measure	Time frame
Liver enzymes (ALT,AST? CPK). Timepoint: Before and after treatment. Method of measurement: Blood test.;White blood cell count. Timepoint: Before and after treatment. Method of measurement: Blood test.;Coagulation factors (PT? PTT? INR ). Timepoint: Before and after treatment. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Jamalian

Arak University of Medical Sciences

Jamalian@arakmu.ac.ir+98 86 3417 3505

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026